Bei der Entstehung von Magengeschw}ren ist in den letzten Jahren die Bedeutung einer Ausl|sung durch Campylobacter pylori bekannt geworden. Neue systematische Untersuchungen f}hrten zu einer Namens{nderung: Helicobacter. Der Band gibt eine Obersicht }ber den derzeitigen Wissensstand.

Covers all aspects of gastrointestinal and liver malignancies (epidemiology, pathophysiology, screening where appropriate, symptoms and clinical signs, diagnostic studies, staging and classification, treatment, prognosis, follow-up, future perspectives). The text is addressed to those involved in the multidisciplinary approach to the gastrointestinal cancer patient (gastroenterologists, medical oncologists, radiation therapists, surgeons, interventional radiologists, pathologists, nurses, and physicians-in-training). The book provides in-depth information, illustrated by numerous color/black-and-white pictures. Selective reading for a quick reference is made possible by introducing text elements such as summaries, tables, listing and treatment algorithms.

The explosion of information on Helicobacter pylori-related disease, both in the basic sciences and in clinical medicine, has continued to progress at an unprecedented pace. In many instances H. pylori infection, both in man and in the laboratory animal, has become a model to investigate fundamental biological issues such as micro-organism host interactions, intracellular signalling, development of mucosal atrophy, mechanism of microbial resistance, disease modifying factors etc. In view of this bewildering flood of information, another meeting on H. pylori in the successful series "Basic mechanisms to clinical cure" was organized in January 1998 in San Diego, California, to define the "state-of-affairs" in H. pylori research at this time. The main objective was to integrate this information in a series of presentations and discussions between investigators and clinicians addressing all aspects of H. pylori research and to review the current position and future research directions. The format included presentations by world experts heavily involved in H. pylori research followed by in-depth discussion on intriguing or controversial issues. The presentations were grouped according to the leading theme: characteristics of the organism, mode of transmission, mechanisms of H. pylori-induced inflammation, causation of disturbances of gastric secretory and motor function, aspects of clinical presentation and management, problems related to H. pylori-associated gastric adenocarcinoma and MALT-lymphoma, novel aspects of antimicrobial therapy and vaccination. The chapters published in these proceedings accurately reflect the content of the presentations. These proceedings are testimony to the impact on basic science and clinical medicine of the H. pylori discovery.

Section I. Basic Bacteriology of H. pylori.- 1. In vivo models of gastric Helicobacter infections.- 2 H. pylori species heterogenicity.- 3 H. pylori urease.- 4 Basic bacteriology of H. pylori: H. pylori colonization factors.- Section II. Prevalence and Mechanisms of Spread of H. pylori.- 5 Epidemiology of H. pylori in Western countries.- 6 H. pylori in developing countries.- 7 Prevalence/disease correlates of H. pylori.- 8 Reinfection with H. pylori.- Section III. Mechanisms of H. pylori Induced Damage.- 9 Breakdown of the mucus layer by H. pylori.- 10 Decreased hydrophobicity of gastroduodenal mucosa due to H. pylori infection in man.- 11 Adherence and internalization of H. pylori by epithelial cells.- 12 Mechanisms of ammonia-induced gastric mucosal injury: role of glutathione and cysteine proteases.- 13 Lipopolysaccharide (LPS)-related damage by H. pylori.- 14 The cpn60 heat shock protein homologue of H. pylori.- 15 Gastric mucosal injury: interactions of mast cells, cytokines and nitric oxide.- 16 H. pylori supernatant contains a novel chemotactic factor for monocytes different from FMLP.- 17 H. pylori-induced neutrophil activation and production of toxic oxygen radicals.- 18 Polymorphonuclear leukocytes traffic into the gastric mucosa and through the gastric mucosal barrier in H. pylori infection: is that bad?.- 19 H. pylori vacuolating toxin.- 20 H. pylori alcohol dehydrogenase.- Section IV. Hormonal Disturbances in H. pylori Infection.- 21 Effect of H. pylori infection on gastrin and gastric acid secretion.- 22 H. pylori, gastrin and somatostatin.- 23 Parietal cell responsiveness in H. pylori infections.- 24 Role of bacterial amines in H. pylori-associated hypergastrinaemia.- 25 Do gastric mucosal nerves remodel in H. pylori gastritis?.- Section V. Immunological Response to H. pylori.- 26 Overview of the immune response to H. pylori.- 27 Specific H. pylori immune response.- 28 B cell responses in H. pylori infection.- 29 T cell subsets in H. pylori-associated gastritis.- 30 Down-regulation of the immune response to H. pylori.- 31 The clinical value of a saliva diagnostic assay for antibody to H. pylori.- Section VI. Gastroduodenal Inflammation in H. pylori Infection.- 32 Spectrum and implications of inflammation with H. pylori.- 33 'Hypertrophic' gastritis in H. pylori infection.- 34 Long-term consequences of H. pylori infection: time trends in H. pylori gastritis, gastric cancer and peptic ulcer disease.- 35 Determinants of gastritis phenotype in H. pylori infection.- 36 The ulcer-associated cell lineage (UACL): a newly-recognised pathway of gastrointestinal differentiation of importance in the natural healing of peptic ulcer disease.- Section VII. Determinants of Clinical Outcome of H. pylori Infection.- 37 Acute infection with H. pylori.- 38 H. pylori in asymptomatic people.- 39 Determinants of clinical outcome of H. pylori infection: duodenal ulcer.- 40 H. pylori and gastric ulcer disease.- 41 Functional dyspepsia and H. pylori: a controversial link.- 42 H. pylori and NSAIDs: a meta-analysis on interactions of acute gastroduodenal injury, gastric and duodenal ulcers and upper gastrointestinal symptoms.- Section VIII. Relationship of H. pylori Gastric Carcinogenesis and Lymphoma.- 43 H. pylori and gastric cancer: the significance of the problem.- 44 The ascorbic acid story.- 45 Role of bacterial overgrowth in gastric carcinogenesis.- 46 The role of PCR techniques in the epidemiology of H. pylori infections.- 47 Role of H. pylori in atrophic gastritis and intestinal metaplasia.- 48 H. pylori-associated gastric lymphoma.- 49 Animal models for Helicobacter-induced gastric and hepatic cancer.- 50 Flaws in H. pylori-related carcinogenesis hypothesis.- Section IX. Therapy of H. pylori Infection.- 51 Determinants of antimicrobial effectiveness in H. pylori gastritis.- 52 Mucosal antibiotic levels.- 53 H. pylori eradication.- 54 H. pylori resistance to antibiotics.- 55 The role of acid suppression in the treatment of H. p...